Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance to co-promote Seroplex to its core healthcare partners
Subscribe to our email newsletter
BioAlliance has signed a co-promotion agreement with Lundbeck for Seroplex antidepressant.
Reportedly, the company would co-promote Seroplex to its core healthcare partners, as part of a comprehensive approach to patient management in general and cancer therapy in particular. This is in line with France’s national guidelines for cancer patients.
Dominique Costantini, president and CEO of BioAlliance, said: We are clearly delighted with Lundbeck’s choice of BioAlliance as a co-promotion partner – a choice which validates the quality of our work and that of our hospital-focused sales team. With Loramyc and now Seroplex (which also has a role in supportive care), BioAlliance is optimizing its sales and marketing resources.